



Docket No.: PA003P1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Rosen et al.

Application No.: 09/997,003

Confirmation No.:

Filed: November 30, 2001

Art Unit: 1634

For: Human Protein HTELE03 (As Amended)

Examiner: A. Chakrabarti

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AP listed on the attached Form PTO/SB/08. A copy of each of references AA-AP is enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference(s) and that the reference(s) be made of record in the file history of the application.


Application No.: 09/997,003

Docket No.: PA003P1

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Dated: October 28, 2003

Respectfully submitted,

By 
Mark J. Hyman

Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(240) 314-1224

MMW/MJH/KC/lcc

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/997,003-Conf. 7261
				Filing Date	November 30, 2001
				First Named Inventor	Craig A. Rosen
				Group Art Unit	1634
				Examiner Name	Chakrabarti, A.
Sheet	1	of	1	Attorney Docket Number	PA003P1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AA	Genbank Accession No. M18963, "Human islet of Langerhans regenerating protein (reg) mRNA, complete cds," (April 1993).		
	AB	Genbank Accession No. R59288, "Human reg protein," (February 1995).		
	AC	Genbank Accession No. AA135289, "zo24f08.r1 Stratagene colon (#937204) Homo sapiens cDNA clone PEROXIDASE-GASTROINTESTINAL (HUMAN);, mRNA sequence," (November 1996).		
	AD	Genbank Accession No. AA569032, "nm23g10.s1 NCI_CGAP_Co10 Homo sapiens cDNA clone IMAGE:1061058 3', mRNA sequence," (September 1997).		
	AE	Genbank Accession No. CAB43534, "Glutathione peroxidase-related protein [Homo sapiens]," (July 1999).		
	AF	Genbank Accession No. NM_002083, "Homo sapiens glutathione peroxidase 2 (gastrointestinal) (GPX2), mRNA," (October 2003).		
	AG	Genbank Accession No. NP_002074, "Gastrointestinal gluathione peroxidase 2 [Homo sapiens]," (October 2003).		
	AH	PIR Accession No. A45207, "Glutathione peroxidase (EC 1.11.1.9) 2 - human," (May 1999).		
	AI	Swiss-Prot Accession No. P18283, "GPX2_HUMAN," (November 1990).		
	AJ	Geneseq Accession No. AAP91790, Toyo Jozo KK and Asahi Kasei Kogoyo KK, (December 1989).		
	AK	Geneseq Accession No. AAC98374, Human Genome Sci. Inc. (September 2000).		
	AL	Geneseq Accession No. AAF75088, Human Genome Sci. Inc. (February 2001).		
	AM	Geneseq Accession No. AAM52464, Univ. Georgia Res. Found Inc. (October 2001).		
	AN	ROSS <i>et al.</i> , "Systemic variation in gene expression patterns in human cancer cell lines," <i>Nature Genetics</i> 24:227-235 (2000).		
	AO	SU <i>et al.</i> , "Molecular classification of human carcinomas by use of gene expression signatures," <i>Cancer Res.</i> 61:7388-7393 (2001).		
	AP	WATSON <i>et al.</i> , "Recombinant DNA," Second Ed. New York: W.H. Freeman & Co. pp. 63-77 (1994).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.